Characteristics of the study population
| Unadjusted urinary BPA at visit 1 (n=94) | |
| Median (IQR) | 1.01 (2.01) |
| 95% CI | 1.19 to 2.57 |
| Mean (SD) | 1.88 (2.68) |
| No of samples below LoQ (0.1 ng/mL) | 15 |
| Minimum value (ng/mL) | 0.07 |
| Maximum value (ng/mL) | 13.55 |
| Creatinine-adjusted urinary BPA at visit 1 (n=94) | |
| Median (IQR) | 1.22 (1.99) |
| 95% CI | 1.16 to 1.20 |
| Mean (SD) | 1.58 (1.64) |
| No of samples below LoQ (0.1 ng/mL) | 15 |
| Minimum value (ng/mL) | 0.05 |
| Maximum value (ng/mL) | 8.56 |
| Unadjusted urinary BPA at visit 2 (n=94) | |
| Median (IQR) | 1.47 (2.87) |
| 95% CI | 1.59 to 3.97 |
| Mean (SD) | 2.78 (4.64) |
| No of samples below LoQ (0.1 ng/mL) | 12 |
| Minimum value (ng/mL) | 0.07 |
| Maximum value (ng/mL) | 31.2 |
| Creatinine-adjusted urinary BPA at visit 2 (n=94) | |
| Median (IQR) | 1.24 (2.51) |
| 95% CI | 1.21 to 5.01 |
| Mean (SD) | 3.13 (7.36) |
| No of samples below LoQ (0.1 ng/mL) | 12 |
| Minimum value (ng/mL) | 0.04 |
| Maximum value (ng/mL) | 53.42 |
| Unadjusted ΔBPA (n=94) | |
| Median (IQR) | 0.06 (2.09) |
| 95% CI | 0.05 to 1.75 |
| Mean (SD) | 0.90 (3.32) |
| Minimum value | −6.42 |
| Maximum value | 17.64 |
| Adjusted ΔBPA (n=94) | |
| Median (IQR) | 0.05 (2.94) |
| 95% CI | −0.28 to 3.39 |
| Mean (SD) | 1.55 (7.16) |
| Minimum value | −4.47 |
| Maximum value | 50.38 |
| BPA risk score (n=94) | |
| Median (IQR) | 17.0 (11.0) |
| 95% CI | 15.4 to 18.8 |
| Mean (SD) | 17.1 (6.63) |
| Demographics (n=94) | |
| Sex (%) male | 44 |
| Exposure to oestrogens (%) of cohort | 15 |
| BMI, median (IQR) | 20.7 (3.43) |
| BMI, mean (SD) | 21.3 (3.13) |
A complete dataset was available on 94 out of 108 participants. The units of BPA and BMI are ng/mL and kg/m2, respectively. Urinary BPA levels are given both as unadjusted data and as a BPA (ng/mL) to creatinine (mg/mL) ratio.
BMI, body mass index; BPA, bisphenol A; LoQ, limit of quantification.